Entacapone has median FTO IC50 of 3.5 microM.
https://stm.sciencemag.org/content/11/488/eaau7116?rss=1
According to Su et al, Bisantrene has IC50 of 142 nM, i.e. about 25 times more potent.
So, dear @RaceOncology, the questions are:
(a) why has Entacapone not been trialled for cancer?
(b) more relevantly for RAC, why has Bisantrene not been trialled for Parkinsons Disease or other CNS diseases?
Note: In the Sheba trial, CNS disease was an exclusion criterion.
- Forums
- ASX - By Stock
- RAC
- The RAC 3-Pillar Trifecta
The RAC 3-Pillar Trifecta, page-166
-
-
- There are more pages in this discussion • 259 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.56 |
Change
0.010(0.65%) |
Mkt cap ! $265.8M |
Open | High | Low | Value | Volume |
$1.55 | $1.56 | $1.51 | $95.69K | 62.25K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 3015 | $1.55 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.56 | 4018 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 3015 | 1.550 |
2 | 17973 | 1.530 |
1 | 19190 | 1.525 |
1 | 20000 | 1.520 |
1 | 500 | 1.500 |
Price($) | Vol. | No. |
---|---|---|
1.560 | 4018 | 1 |
1.570 | 4602 | 2 |
1.580 | 15715 | 3 |
1.600 | 2319 | 1 |
1.645 | 10000 | 1 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online